Title: Chapter 32 drug used in digestive system
1Chapter 32drug used in digestive system
2- This chapter describes drugs used to treat these
common medical conditions involving the
gastrointestinal tract - peptic ulcers, dyspepsia, vomitting, diarrhea and
constipation, etc.
3 Part ? Drugs Used in Peptic Ulcer
4peptic ulcer
- A benign, localized defect in the mucosa of
any part of the gastrointestinal tract. - duodenal ulcer
gastric ulcer
5Symptoms and complications
- The most important symptom is abdominal pain and
discomfort. The atypical symptoms are abdomen
distention, inappetence, belching, reflux of
gastric acid. - The severe complications are hemorrhage,
perforation, obstruction and canceration.
6Pathogenesis of peptic ulcer
- although the pathogenesis of peptic ulcer disease
is not fully understood, - the theory that the balance between mucosal
defense and injury is broken are recognized.
7- Pathogenesis of peptic ulcer
- 1. Aggressive factors?
- Helicobacter Pylori ( H. Pylori)
- gastric acid and pepsin
- 2. Defensive factors?
- mucus-bicarbonate barrier
- prostaglandins
8Helicobacter Pylori ( H. Pylori)
- In 1983, H. pylori was found by two Australians,
Marshall and Warren. - Now, it is believed that H. pylori is the most
important pathogenic factor to peptic ulcer. - No H.P., no ulcer.
- And the two men won the noble prize for the
important findings in 2005.
9H. Pylori (48,000)
10H. Pylori on gastric mucosa(16,000)
11Actions of H. Pylori
12gastric acid and pepsin
- Pepsin can decompose protein molecule. But its
activity is depended on the pH value. When local
pH value elevates to 4, pepsin cant work well. - Gastric acid is the key-factor of the formation
of peptic ulcer. we can also say that No acid,
no ulcer.
13mucus-bicarbonate barrier
- The epithelial layer of the mucosa is
composed of tightly adjoined cells that are
specialized for existence in an acid medium.
Their tight junctions, synthesis of PGs and
secretion of mucus and bicarbonate all contribute
to maintenance of the epithelial barrier.
14mucus-bicarbonate barrier
15Prostaglandins(PGs)
- Prostaglandins are thought to enhance resistance
to injury by maintaining blood flow to the
mucosa. - Thus it also plays a major role in the
maintenance of defensive mechanism.
16- Classification of drugs
- ?.Antacids
- ?.Agents decreasing secretion of
- gastric acid
- ?. Agents protecting mucosal barrier
- ?.Agents eradicating helicobacter
- pylori
17? Antacids
- Have been used for centuries in the treatment of
patients with acid-peptic disorders. - Were the mainstay of treatment for acid-peptic
disorders until the advent of H2-receptor
antagonists and proton pump inhibitors.
18? Antacids
- weak bases Mg(OH)2 , Al(OH)3 ,
- CaCO3 , NaHCO3
- actions
- 1) prevent injury from H
- 2) neutralize gastric acid ? reduce gastric
acidity? reduce peptic activity - 3) protect face of ulcer( Mg2SiO8 Al(OH)3 )
19- ? Antacids
- NaHCO3HCl ? NaclH2OCO2?
- Mg2Si3O84HCl ? 2MgCl23SiO2
- Al(OH)33HCl ? AlCl33H2O
- Mg(OH)2HCl ? MgCl22H2O
- CaCO32HCl ? CaCl2H2OCO2 ?
- MgOHCl ? MgCl2H2O
20- ?1?????????????
- NaHCO3 Mg2SiO8 Al(OH)3 Mg(OH)2
CaCO3 MgO - 1g???0.1 120 150
250 210 200 500 - N?HCl ml?
- ???? ?? ?? ???
??? ??? ?? - ?????? ? ?
?? ?? ?? ?? - ????? ? ?
? ? ? ? - ???? ? ?
? ? ? ? - ??CO2 ? ?
? ? ? ? - (??)
- ???? ? ?
? ? ? ? - ???? ? ?
? ? ? ? - ????? ? ?
? ? ? ?
??
??
??
21- side reactions
- disorder of gastrointestinal track
- diarrhea constipation belching(??)
flatulence (????) - alkalemia
22? Agents reducing secretion of gastric acid
23Regulation of gastric acid secretion
24- Drugs reducing secretion of gastric acid
- (1) H2-receptor antagonists
- (2) Antimuscarinic agents
- (3) Inhibitors of the proton pump
- (4) gastrin-receptor antagonists
25H2-R antagonists
- Cimetidine, Ranitidine, Famotidine , Nizatidine
- Actions
- Competitively block the binding of histamine
to H2 receptor. Completely inhibit gastric
acid secretion induced by histamine. - characteristics
- more effective than M-R antagonistslong
duration high rate of healing up rebound
26Regulation of gastric acid secretion
27Cimetidine(????????)
- Pharmacokinetics
- Absorption p.o F70
- Distribution widely
- Elimination kidney
- ! Heptic microsomal enzyme inhibitor
- Action
- inhibit all kinds of gastric acid secretion
28Clinical uses
- ?peptic ulcersÂ
- effective in promoting healing of peptic ulcers.
400 mg bid 4W?80 healing - after treatment is stopped, recurrence is common.
This can be effectively prevented by eradication
of H.Pylori.
29- ?Zollinger-Ellison syndrome a fatal disorder in
which a gastrin-producing tumor causes
hypersecretion of gastric acid. - In many patients, H2 receptor antagonists can
effectively keep the acid secretion to safe
levels so as to control symptoms related to
excess acid secretion.
30- ?gastroesophageal reflux disorder
- (GERD, heartburn)
- Because they act through stopping acid secretion,
they may not relieve symptoms of heartburn for at
least 45 minutes. - Antacid will be more efficiently to neutralize
secreted acid already in the stomach.
31Adverse reactions
- 1.the common side effects are
- headache, dizziness, diarrhea and muscular
pain, skin rash - 2.CNS effects
- confusion, disorientation and hallucination
- 3. Endocrine system effects gynecomastia,
impotency, galactorrhea(??)
32- Ranitidine(????)
- 1) Antisecretive effect is 10 times that
of Cimetidine . - 2)Less effect on hepatic microsomal
metabolism system. - 3)Longer duration and less
antiandrogenic effect
33- Famotidine(????)
- 1) Antisecretive effect is 40 times that of
Cimetidine . - 2) Have no effect on hepatic microsomal
metabolism system. - Nizatidine(????)
- Ebrotidine(????)
- 1) ?Expression of EGF and
PDGF?stimulate proliferation of epithelium - 2) increase mucus secretion
34Inhibitors of the proton pump
- Omeprazole, lansoprazole, pantoprazole
-
- pharmacological effects
- Inhibits H being transported to gastric lumen
through inhibiting the proton pump. - Potent and long-lasting effect Can inhibit over
95 of gastric acid secretion. - Also inhibit release of peptin and H.P
35Regulation of gastric acid secretion
36Clinical uses
- ?peptic ulcer was judged to be superior to
H2-R antagonists - ?Zollinger-Ellison syndrome
- ? heartburn the most effective agents.
- ?hemorrhage of upper digestive tract
- ? H.P infection
-
37Adverse reactions extremely safe
- 1)G.I reactions nausea,vomitting, diarrhea,
abdominal pain etc. - 2)NS headache, swirl, insomnia, peripheral
neuritis, etc. - 3) overgrowth of bacteria Increases in gastric
bacterial concentrations. - 4)hypergastrinemia(??????)
- 5)canceration
38- Omeprazole
- Easily absorbed, but affected by food
- Is also heptic enzyme inhibitor
- lansoprazole second generation
- Pantoprazole and rabeprazole
- third generation
- weak effect on heptic enzyme
39Antimuscarinic agents
- Muscarinic receptor stimulation increase
gastrointestinal motility and secretion. - So cholinergic antagonists can be used as
adjuncts in the management of peptic ulcer
disease and Zollinger-Ellison syndrome,
particularly in patients refractory to standard
therapies.
40Regulation of gastric acid secretion
41Antimuscarinic agents
- In contrast to the classic anticholinergics, the
relatively specific M1-receptor antagonist,
Pirenzepine is a good choice as an
anti-secretory agent. Because it suppresses basal
and stimulated gastric acid secretion at doses
having a minimal effect on other organs (salivary
glands, the heart and eye.)
42- gastrin-receptor antagonists
- proglumide(???)
43? Agents protecting mucosal barrier
- (1)Prostaglandins
- (2)Mucosal protective agents
44- Prostaglandins
- prostaglandins E2 and I2, produced by the gastric
mucosa, inhibit secretion of gastric acid and
stimulate secretion of mucus and bicarbonate
(cytoprotective effect) . - A deficiency of prostaglandins is thought to be
involved in the pathogenesis of peptic ulcers.
45Mucosal protective agents
- These compounds, known as cytoprotective ones ,
have several actions that enhance mucosal
protection mechanisms, thereby preventing mucosal
injury, reducing inflammation and healing
existing ulcers. - clinical uses NSAID-induced ulcer
- adverse reactions dose-dependent diarrhea,
stimulate uterus
46Misoprostol a stable analog of PGE2
- (1) inhibits secretion of gastric acid and
stimulate secretion of mucus and bicarbonate. - (2) dilate blood vessel of mucous membrane.
- (3) currently the only agent approved for
prevention of gastric ulcers induced by NSAIDs. - (4)less effective than H2-receptor antagonists
for acute treatment of peptic ulcers. - (5)produces uterine contractions and is
contraindicated during pregnancy.
47Mucosal protective agents
- Sucralfate(???)
- 1)In water or acidic solutions it forms a
viscous, tenacious paste that binds selectively
to ulcers or erosions for up to 6 hours. - 2)Also stimulates prostaglandin release and mucus
and bicarbonate output. - 3)Promote effects of growth factors
- 4)Inhibit H.P
- ! Needs acid envioment affects absorption of
other drugs
48Mucosal protective agents
- colloidal bismuth subcitrate (?????)
- 1) binds to an ulcer crater, coating it and
protecting it from acid and pepsin. - 2) Inhibits the activity of pepsin
- 3) increases mucous secretion
- 4) increase prostaglandin synthesis
- 5) helps to eradicate H. pylori
49Antimicrobial agents
- Optimal therapy of patients with peptic ulcer
disease who are infected with H.Pylori requires
antimicrobial treatment. - Eradication of H.Pylori results in rapid healing
of active peptic ulcers and low recurrence rates. - Metronidazole, tetracycline, amoxiciliin, etc.
- Often combined with other drugs.
50- Section 2
- Drugs modulating digestive function
- ? Digestants
- Dilute hydrochloric acid
- Pepsin
- Pancretin
- biofermin
-
51? Antiemetic and prokinetic agents
52- ? Antiemetic and prokinetic agents
- ? Antiemetic agents
- 1. H1-receptor antagonist
- Dimenhydrinate (???)
-
- 2. M-receptor antagonist
- scopolamine
-
533. dopamine antagonists
- Metoclopramide(?????)
- mechanism
- 1) block D2-receptor in CTZ ? antinausea and
antiemetic action - 2) block gastrointestinal D2-receptor
- ? promote vermiculation(???)
-
54- Clinical use
- prevention of vomitting
- gastrointestinal reflux disease
- nonulcer dyspepsia
- impaired gastric emptying
- adverse reaction
- extrapyramidal symptoms,
- especially dystonias(????)
55- Domeperidone (????)
- block gastrointestinal D2-receptor
- ? promote vermiculation
- Cisapride(????)
- DA, Ach, 5-HT
56- 4. 5-HT3 inhibitor
- ondansetron
- used in the prevention of chemotherapy-induced
and postoperative nausea and vomiting - Granisetron(????)
- Tropisetron(????)
57- ? Antidiarrheal agents
-
- Increased motility of the gastrointestinal
tract and decreased absorption of fluid are major
factors in diarrhea. - So antidiarrheals include anti-motility agents,
adsorbents and drugs that modify fluid and salt
transport.
58- 1.Opium receptor agonists
- Opium tincture
- Tincture camphor compound
- Diphenoxylate (????)
- Loperamide(????)
59- Diphenoxylate(????)
- Opioids are the most effective agents for relief
of diarrhea. - Is an analog of pethidine and have opioid-like
actions on the gut. - block gastrointestinal µ-receptor ? decrease
vermiculation(???) - Is used to control acute or chronic functional
diarrhea - difficultly penetrate BBB, have no extrapyramidal
symptoms
60- 2.Astringents(???)
- Tannalbin(????)
- 3.Absorbants
- Medical charcoal, Smectite(???),kaolin ,
and pectin - They act as absorbents of bacteria,
toxins, and fluid, thereby decreasing stool
liquidity and quantity. They may be useful in
acute diarrhea but are seldom used on a chronic
basis.
61- ? Laxatives(??)
- 1.Contact laxatives
- Phenolphthalein(??), Bisacodyl(????)
- Anthraquinones(??) rhubarb(??).senna(???)
- 2.Osmotic laxatives
- Magnesium sulfate
62- Machanism
- form gels in the large intestine, causing
water retention and intestinal distension,
thereby increasing motility. - Effects and uses
- (1)Diarrhea
- (2) Cholagogic(???) action
- (3) Relax skeletal muscles
- (4)Relax vascular smooth muscle
63- Sodium sulfate, Lactulose(???), Glycerol
(??), castor oil(???) , celluloses(???) - 3. Stool softeners
- Liquid paraffin(??)
- ? Choleretics (learn by yourself)
64Thank you!